Gene Therapy Firm Freeline Successfully Tops Up Series C

Freeline Therapeutics Ltd. has topped up an original series C financing with a further $80m from specialist global institutional investors for a total of $120m. This will give the gene therapy specialist an extended financial runway for advancing its lead program in hemophilia B into a pivotal trial next year and its Phase I/II clinical program for Fabry disease as well as progressing its pipeline for Gaucher disease and hemophilia A, the UK-based group’s CEO told Scrip.

The augmented series C round was led by Novo Holdings A/S, Eventide Asset Management and Wellington Management Company, with additional participation from Cowen Healthcare Investments, Acorn Bioventures and Ample Plus Fun. Freeline's founding investors, including Syncona, had previously backed the company two years ago with £34.8m and £88.4m series A and B rounds, respectively